Holen Sie sich die Stockscreener-App
1.50
2.60%
-0.04
Schlusskurs vom Vortag:
$1.54
Offen:
$1.5
24-Stunden-Volumen:
20,574
Relative Volume:
0.22
Marktkapitalisierung:
$533.08M
Einnahmen:
$863.66M
Nettoeinkommen (Verlust:
$-225.27M
KGV:
-2.3652
EPS:
-0.6342
Netto-Cashflow:
$-63.28M
1W Leistung:
+8.70%
1M Leistung:
-2.60%
6M Leistung:
-53.56%
1J Leistung:
-62.87%
1-Tages-Spanne:
$1.50
$1.53
1-Wochen-Bereich:
$1.41
$1.56
52-Wochen-Spanne:
$1.33
$4.27
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
1.50 | 533.08M | 863.66M | -225.27M | -63.28M | -0.6342 |
TAK
Takeda Pharmaceutical Co Adr
|
20.24 | 64.66B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.41 | 45.96B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.27 | 45.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
81.03 | 33.48B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
587.50 | 25.20B | 3.17B | 1.29B | 1.01B | 27.09 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-16 | Herabstufung | Berenberg | Buy → Hold |
| 2026-07-15 | Herabstufung | TD Cowen | Buy → Hold |
| 2026-04-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2026-02-03 | Eingeleitet | Berenberg | Buy |
| 2025-04-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2024-08-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-07-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-04-04 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-08-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-01-07 | Fortgesetzt | Citigroup | Neutral |
Alle ansehen
Evotec Se Adr Aktie (EVO) Neueste Nachrichten
A €2.5109-per-share block trade ends an investment in Evotec SE (EVO). - Stock Titan
EVO Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus, Shares Still Slip 1.82%Next Quarter Guidance - https://www.dars.gov.et/
BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in Cologne - GlobeNewswire Inc.
Evotec SE (NASDAQ: EVO) Initiates First Human Trial for JST-018 Under 2023 Accelerated Antibodies Contract - Kalkine Media
Evotec starts Phase 1 trial for JST-018 antibody therapy - grafa.com
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
EVO Q2 2026 Earnings: Sharply Narrower $0.26 per-ADS Loss Beats Forecast, Yet Stock Falls 4.26%Earnings Manipulation Risk - dars.gov.et
EVO Q2 2026 Earnings: Sharply Narrower $0.26 per-ADS Loss Beats Forecast, Yet Stock Falls 4.26%Cash Flow Report - dars.gov.et
Evotec SE (EVO) Rebounds 2.12% as Shares Approach Key $2.03 ResistanceFloat Adjusted Cap - dars.gov.et
Evotec SE (EVO) Rebounds 2.12% as Shares Approach Key $2.03 ResistanceDaily Profile - careplusvn.com
EVO Q1 2026 Earnings: Wider-than-Expected Loss Despite Stock RiseNet Income Trends - dars.gov.et
Evotec SE (EVO) Rebounds 2.12% as Shares Approach Key $2.03 ResistanceLast Point Resistance - dars.gov.et
EVO Q1 2026 Earnings: Wider-than-Expected Loss Despite Stock RiseSurprise Factor Analysis - www.dars.gov.et
Evotec stock struggles after profit warning as Q2 2026 figures and guidance cuts weigh on sentiment - ad-hoc-news.de
Evotec (EVO) Quarterly Figures: The Available Earnings Metric Delivers a Miss for the Current Session; Closing Reaction: The Stock Loses 1.53% in Latest TradingPre-Earnings Setup - dars.gov.et
Evotec stock trades close to 52-week low as Q2 revenue declines - ad-hoc-news.de
Evotec (EVO) Momentum: Loses 3.03% to Close at $1.92 in Latest Trading; Chart Watch: Price Remains Between $1.82 Support and $2.02 Resistance for the Current SessionMomentum ETF - dars.gov.et
Evotec (EVO) Financial Update: The EPS Result Is Below Expectation in the Latest Session; Share Response: The Stock Ends Up 3.66% in the Latest ReadingProfit Cycle Analysis - careplusvn.com
Evotec (EVO) Earnings Snapshot: The EPS Result Is Below Expectation in the Latest Session; Stock Move: The Market Price Declines 3.03% in Latest TradingAnalyst Drop Coverage - careplusvn.com
Evotec (EVO) Financial Update: The EPS Result Is Below Expectation in the Latest Session; Share Response: The Stock Ends Up 3.66% in the Latest ReadingEarnings Season Review - dars.gov.et
Evotec (EVO) Momentum: Loses 3.03% to Close at $1.92 in Latest Trading; Chart Watch: Price Remains Between $1.82 Support and $2.02 Resistance for the Current SessionLow Volume Node - www.dars.gov.et
Evotec (EVO) Momentum: Loses 3.03% to Close at $1.92 in Latest Trading; Chart Watch: Price Remains Between $1.82 Support and $2.02 Resistance for the Current SessionScalping Stock Signals - www.dars.gov.et
Evotec (EVO) Financial Update: The EPS Result Is Below Expectation in the Latest Session; Share Response: The Stock Ends Up 3.66% in the Latest ReadingReturn On Assets - www.dars.gov.et
Evotec stock trades at a discount to recent analyst targets as Xetra shares retreat - ad-hoc-news.de
Evotec stock trades well below analyst targets as selling pressure intensifies - Ad-hoc-news.de
Evotec stock faces earnings estimate cut as ADR trades below $2 - ad-hoc-news.de
Evotec (EVO) Earnings Brief: EPS Comes in Below Forecast on the Day; Market Follow-Through: Shares Move 2.55% DownEarnings Cycle Report - dars.gov.et
Evotec (EVO) Earnings Brief: EPS Comes in Below Forecast on the Day; Market Follow-Through: Shares Move 2.55% DownEstimate Revision Count - dars.gov.et
Evotec AG Earnings Call: Weak 2026, Pipeline Hopes - The Globe and Mail
Evotec stock weakens after Q2 2026 miss and guidance cut - AD HOC NEWS
Evotec SE (EVO) Rebounds 4% to $2.08 as Drug Discovery Sector StabilizesETF NAV Deviation - careplusvn.com
Evotec signs AI drug discovery partnership with Odyssey - grafa.com
Evotec SE (EVO) Holds Near $1.95 as Shares Consolidate Above Key SupportFactor ETF Flow - dars.gov.et
Evotec SE (EVO) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesPost-Earnings Reaction - vinanet.vn
Evotec SE (EVO) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesSaaS Earnings Trends - dars.gov.et
Berenberg cuts Evotec on delayed pharma deals clouding revenue outlook - Investing.com
Berenberg cuts Evotec stock rating on guidance downgrade By Investing.com - Investing.com Nigeria
Berenberg cuts Evotec stock rating on guidance downgrade - Investing.com
Berenberg cuts Evotec stock rating on guidance downgrade By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
TD Cowen cuts Evotec on customer delays clouding growth outlook By Investing.com - Investing.com Nigeria
TD Cowen cuts Evotec on customer delays clouding growth outlook - Investing.com
H.C. Wainwright cuts Evotec stock price target on revenue guidance reduction - Investing.com
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
TD Cowen cuts Evotec stock rating on revenue delays, lowers target to $2 - Investing.com Nigeria
TD Cowen cuts Evotec stock rating on revenue delays, lowers target to $2 - Investing.com
TD Cowen cuts Evotec stock rating on revenue delays, lowers target to $2 - Investing.com Canada
Evotec (EVO) Slips Over 6% as Shares Test Key Support at $1.91Weak Sell Signals - careplusvn.com
Evotec (EVO) Slips Over 6% as Shares Test Key Support at $1.91Gap Up Stocks - dars.gov.et
Evotec (EVO) Slips Over 6% as Shares Test Key Support at $1.91Standard Deviation - www.dars.gov.et
Finanzdaten der Evotec Se Adr-Aktie (EVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.15%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):